Development of peptide vaccines inducing production of neutralizing antibodies against HIV-1 viruses in HLA-DQ6 mice

Vaccine

Volumn 16, Issue 16, 1998, Pages 1537-1543

  Takahashi, Akio ^a   Ogasawara, Kazumasa ^a   Matsuki, Naoto ^a   Fujinaga, Koh ^a   Nakaya, Takaaki ^a   Ikuta, Kazuyoshi ^a   Auwanit, Wattana ^b   Honda, Mitsuo ^c   Fukui, Yoshinori ^d   Sasazuki, Takehiko ^d   Iwabuchi, Kazuya ^a   Onoé, Kazunori ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

AIDS HIV; In vivo animal models; MHC

Indexed keywords

AMINO ACID; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; PEPTIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE;

AIDS VACCINES; ANIMALS; HIV ANTIBODIES; HIV-1; HLA-DQ ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEUTRALIZATION TESTS; T-LYMPHOCYTES; VACCINES, SYNTHETIC;

EID: 17144432467     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00042-5     Document Type: Article

References (33)

1. 1 Palker, T. J., Clark, M. E., Langlois, A. J., Matthews, T. J., Weinhold, K. J., Randall, R. R., Bolognesi, D. P. and Haynes, B. F. Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic peptides. Proc. Natl Acad. Sci. USA 1988, 85, 1932-1936.
2. 2 Rusche, J. R., Javaherian, K., McDanal, C., Petro, J., Lynn, D. L., Grimaila, R., Langlois, A., Gallo, R. C., Arthur, L. O., Fischinger, P. J., Bolognesi, D. P., Putney, S. D. and Matthews, T. J. Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120. Proc. Natl Acad. Sci. USA 1988, 85, 3198-3202.
3. 3 Goudsmit, J., Debouck, C., Meloen, R. H., Smit, L., Bakker, M., Asher, D. M., Wolff, A. V., Gibbs, C. J. Jr. and Gajdusek, D. C. Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees. Proc. Natl Acad. Sci. USA 1988, 85, 4478-4482.
4. 4 Nara, P. L., Garrity, R. R. and Goudsmit, J. Neutralization of HIV-1: a paradox of humoral proportions. Faseb J. 1991, 5, 2437-2455.
5. 5 Javaherian, K., Langlois, A. J., McDanal, C., Ross, K. L., Eckler, L. I., Jellis, C. L., Profy, A. T., Rusche, J. R., Bolognesi, D. P., Putney, S. D. and Matthews, T. J. Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein. Proc. Natl Acad. Sci. USA 1989, 86, 6768-6772.
6. 6 Javaherian, K., Langlois, A. J., LaRosa, G. J., Profy, A. T., Bolognesi, D. P., Herlihy, W. C., Putney, S. D. and Matthews, T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science 1990, 250, 1590-1593.
7. 7 Steimer, K. S., Scandella, C. J., Skiles, P. V. and Haigwood, N. L. Neutralization of divergent HIV-1 isolates by conformation-dependent human antibodies to gp120. Science 1991, 254, 105-108.
8. 8 Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler, J. A., McCutchan, F. E., Mascola, J., Ho, D. D., Robinson, J. and Conley, A. J. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 1995, 69, 122-130.
9. 9 Berman, P. W., Gregory, T. J., Riddle, L., Nakamura, G. R., Champe, M. A., Porter, J. P., Wurm, F. M., Hershberg, R. D., Cobb, E. K. and Eichberg, J. W. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990, 345, 622-625.
10. 10 Emini, E. A., Nara, P. L., Schleif, W. A., Lewis, J. A., Davide, J. P., Lee, D. R., Kessler, J., Conley, S., Matsushita, S., Putney, S. D., Gerety, R. J. and Eichberg, J. W. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 1990, 64, 3674-3678.
11. 11 Girard, M., Kieny, M. P., Pinter, A., Barre-Sinoussi, F., Nara, P., Kolbe, H., Kusumi, K., Chaput, A., Reinhart, T., Muchmore, E., Ronco, J., Kaczorek, M., Gomard, E., Gluckman, J. C. and Fultz, P. N. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 1991, 88, 542-546.
12. 12 Emini, E. A., Schleif, W. A., Nunberg, J. H., Conley, A. J., Eda, Y., Tokiyoshi, S., Putney, S. D., Matsushita, S., Cobb, K. E., Jett, C. M. and Eichburg, J. W. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992, 355, 728-730.
13. 13 Ogasawara, K., Naruse, H., Itoh, Y., Gotohda, T., Arikawa, J., Kida, H., Good, R. A. and Onoé, K. A strategy for making synthetic peptide vaccines. Proc. Natl Acad. Sci. USA 1992, 89, 8995-8999.
14. 14 Naruse, H., Ogasawara, K., Kaneda, R., Hatakeyama, S., Itoh, T., Kida, H., Miyazaki, T., Good, R. A. and Onoé, K. A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years. Proc. Natl Acad. Sci. USA 1994, 91, 9588-9592.
15. 15 Hammer, J., Valsasnini, P., Tolba, K., Bolin, D., Higelin, J., Takacs, B. and Sinigaglia, F. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993, 74, 197-203.
16. 16 Itoh, Y., Ogasawara, K., Takami, K., Gotohda, T., Naruse, H., Good, R. A. and Onoé, K. Determination of amino acids on agretopes of pigeon cytochrome c related peptides specifically bound to H-2A allelic products. Eur. J. Immunol. 1994, 24, 76-83.
17. 17 Alexander, J., Sidney, J., Southwood, S., Ruppert, J., Oseroff, C., Maewal, A., Snoke, K., Serra, H. M., Kubo, R. T., Seite, A. and Grey, H. M. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994, 1, 751-761.
18. 18 Honda, M., Matsuo, K., Nakasone, T., Okamoto, Y., Yoshizaki, H., Kitamura, K., Sugiura, W., Walanabe, K., Fukushima, Y., Haga, S., Katsura, Y., Tasaka, H., Komuro, K., Yamada, T., Asana, T., Yamazaki, A. and Yamazaki, S. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmetle-Guerin veclor candidate vaccine for human immunodeficiency virus type 1 in small animals. Proc. Natl Acad. Sci. USA 1995, 92, 10693-10697.
19. 19 Nishimura, Y., Iwanaga, T., Inamitsu, T., Yanagawa, Y., Yasunami, M., Kimura, A., Hirokawa, K. and Sasazuki, T. Expression of the human MHC, HLA-DQw6 genes alters the immune response in C57BL/6 mice. J. Immunol. 1990, 145, 353-360.
20. 20 Gosgrove, D., Gray, D., Dierich, A., Kaufman, J., Lemeur, M., Benoist, C. and Mathis, D. Mice lacking MHC class II molecules. Cell 1991, 66, 1051-1066.
21. 21 Janeway, C. J. Monoclonal antibodies specific for la glycoproteins raised by immunization with activated T cells: possible role of T cell bound la antigens as targets of immune regulatory T cell. Immunology 1984, 132, 662-667.
22. 22 Fujinaga, K., Zhong, Q., Nakaya, T., Kameoka, M., Meguro, T., Yamada, K. and Ikuta, K. Exlracellular Nef protein regulates produclive HIV-1 infection from latency. J. Immunol. 1995, 155, 5289-5298.
23. 23 Brown, J. H., Jardelzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L. and Wiley, D. C. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993, 364, 33-39.
24. 24 Sinigaglia, F. and Hammer, J. Motifs and supermotifs for MHC class II binding peptides. J. Exp. Med. 1995, 181, 449-451.
25. 25 Sinigaglia, F., Guttinger, M., Kilgus, J., Doran, D. M., Matile, H., Etlinger, H., Trzeciak, A., Gillessen, D. and Pink, J. R. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988, 336, 778-780.
26. 26 Ceppellini, R., Frumento, G., Ferrara, G. B., Tosi, R., Chersi, A. and Pernis, B. Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells. Nature 1989, 339, 392-394.
27. 27 Panina-Bordignon, P., Tan, A., Termijtelen, A., Demotz, S., Corradin, G. and Lanzavecchia, A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur. J. Immunol. 1989, 19, 2237-2242.
28. 28 Hill, C. M., Hayball, J. D., Allison, A. A. and Rothbard, J. B. Conformational and structural characteristics of peptides binding to HLA-DR molecules. J. Immunol. 1991, 147, 189-197.
29. 29 O'Sullivan, D., Arrhenius, T., Sidney, J., Del Guercio, M. F., Albertson, M., Wall, M., Oseroff, C., Southwood, S., Colon, S. M., Gaeta, F. C. and Sette, A. On the interaction of promiscuous antigenic peptides with different DR alleles: identification of common structural motifs. J. Immunol. 1991, 147, 2663-2669.
30. 30 Roche, P. A. and Cresswell, P. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 1990, 144, 1849-1856.
31. 31 Katoh, M., Itoh, Y., Ogasawara, K., Kajino, K., Nishihori, H., Takahashi, A., Matsuki, N., Iwabuchi, K., Yoshida, T. O., Good, R. A. and Onoé, K. A promiscuous T cell hybridoma restricted to various H-2A molecules. Eur. J. Immunol. 1996, 26, 976-980.
32. 32 Sidney, J., Grey, H. M., Kubo, R. T. and Sette, A. Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol. Today 1996, 17, 261.
33. 33 Imanishi, T., Akaza, A., Kimura, K., Tokunaga, K. and Gojobori, T. Allele frequencies of DNA-typed HLA loci. In HLA 1991 (Eds Tuji, K., Aizawa, M. and Sasazuki, T.). Oxford University Press, New York, 1992, pp. 1065-1220.